177 related articles for article (PubMed ID: 37713593)
21. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
Nagakubo Y; Hirotsu Y; Yoshino M; Amemiya K; Saito R; Kakizaki Y; Tsutsui T; Miyashita Y; Goto T; Omata M
Sci Rep; 2024 May; 14(1):12480. PubMed ID: 38816489
[TBL] [Abstract][Full Text] [Related]
22. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.
Ju S; Cui Z; Hong Y; Wang X; Mu W; Xie Z; Zeng X; Su L; Lin X; Zhang Z; Zhang Q; Song X; You S; Chen R; Chen W; Xu C; Zhao J
Cancer; 2023 Aug; 129(15):2422-2430. PubMed ID: 37096747
[TBL] [Abstract][Full Text] [Related]
23. Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Seker-Cin H; Tay TKY; Kazdal D; Kluck K; Ball M; Neumann O; Winter H; Herth F; Heußel CP; Savai R; Schirmacher P; Thomas M; Budczies J; Allgäuer M; Christopoulos P; Stenzinger A; Volckmar AL
Lung Cancer; 2023 Oct; 184():107317. PubMed ID: 37586177
[TBL] [Abstract][Full Text] [Related]
24. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
25. Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.
Joshi P; Gogte P; Pai T; Gurav M; Dhanawade D; Karnik N; Deshpande G; Kaushal R; Shetty O
Int J Exp Pathol; 2024 Jun; 105(3):90-99. PubMed ID: 38717047
[TBL] [Abstract][Full Text] [Related]
26. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.
Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J
Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889
[TBL] [Abstract][Full Text] [Related]
27. Real-World Evidence Study of Patients with
Anttalainen A; Pietarinen P; Tuominen S; Mattila R; Mutka A; Knuuttila A
Curr Oncol; 2024 May; 31(5):2700-2712. PubMed ID: 38785486
[TBL] [Abstract][Full Text] [Related]
28. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
Kuang X; Xiao J; Dai LX; Zhang LH; He BX
Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
[TBL] [Abstract][Full Text] [Related]
29. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
30. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
Jiagge E; Jin DX; Newberg JY; Perea-Chamblee T; Pekala KR; Fong C; Waters M; Ma D; Dei-Adomakoh Y; Erb G; Arora KS; Maund SL; Njiraini N; Ntekim A; Kim S; Bai X; Thomas M; van Eeden R; Hegde P; Jee J; Chakravarty D; Schultz N; Berger MF; Frampton GM; Sokol ES; Carrot-Zhang J
Cancer Cell; 2023 Nov; 41(11):1963-1971.e3. PubMed ID: 37890492
[TBL] [Abstract][Full Text] [Related]
31. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Cohen D; Hondelink LM; Solleveld-Westerink N; Uljee SM; Ruano D; Cleton-Jansen AM; von der Thüsen JH; Ramai SRS; Postmus PE; Graadt van Roggen JF; Hoppe BPC; Clahsen PC; Maas KW; Ahsmann EJM; Ten Heuvel A; Smedts F; van Rossem RN; van Wezel T
J Thorac Oncol; 2020 Jun; 15(6):1000-1014. PubMed ID: 32014610
[TBL] [Abstract][Full Text] [Related]
32. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
33. Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
Kumbrink J; Demes MC; Jeroch J; Bräuninger A; Hartung K; Gerstenmaier U; Marienfeld R; Hillmer A; Bohn N; Lehning C; Ferch F; Wild P; Gattenlöhner S; Möller P; Klauschen F; Jung A
Pathol Oncol Res; 2024; 30():1611590. PubMed ID: 38605929
[TBL] [Abstract][Full Text] [Related]
34. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
35. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
[TBL] [Abstract][Full Text] [Related]
37. Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
Lim SM; Lee JB; Oya Y; Nutzinger J; Soo R
JCO Oncol Pract; 2024 Jan; 20(1):47-56. PubMed ID: 37733983
[TBL] [Abstract][Full Text] [Related]
38. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
40. Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice.
Garinet S; Lupo A; Denize T; Loyaux R; Timsit S; Gazeau B; Fabre E; Maaradji Z; Gibault L; Giroux-Leprieur E; Duchemann B; Monnet I; Jouveshomme S; Aldea M; Besse B; Le Pimpec-Barthes F; Leroy K; Wislez M; Blons H
Pathology; 2024 May; ():. PubMed ID: 38834439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]